Several randomized clinical trials have shown that implantable cardioverter defibrillator (ICD) therapy reduces morbidity and mortality in patients with heart failure and an impaired ejection fraction at risk for sudden cardiac death.[@bib1], [@bib2], [@bib3], [@bib4], [@bib5] The results of these primary prevention ICD trials form the basis of guideline recommendations that help physicians identify patients who would benefit from this lifesaving therapy.[@bib6], [@bib7], [@bib8], [@bib9] However, data regarding the number of patients these guideline recommendations apply to and use of ICD therapy in clinical practice are sparse.[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17] These data would be important to benchmark care and to identify potential strategies for improvement where gaps exist.

Prior observational studies from both inpatient and outpatient cohorts have found approximately half of patients with heart failure were eligible for a primary prevention ICD.[@bib10], [@bib11], [@bib17] Among eligible patients, use of ICD therapy has ranged from 13%[@bib14] to as high as 87%.[@bib15] The low rates of ICD use were reported from large databases,[@bib12], [@bib14] in which contraindications or reasons for nonimplantation were not available for abstraction. Although the higher rates of ICD use[@bib10], [@bib15], [@bib16] were reviewed by using chart-level data, these studies were limited by small sample sizes,[@bib11], [@bib17] single-center studies,[@bib10], [@bib11], [@bib12] or eligibility criteria mainly focused on a reduced ejection fraction without capturing all eligible patients.[@bib10] Even among large randomized clinical trials for heart failure therapy, ICD use is low, ranging from 5% to 15%.[@bib18], [@bib19] Given the growing population with heart failure[@bib20], [@bib21], [@bib22] and the higher proportion of patients eligible for device therapy, a better understanding of device eligibility and use is needed.

Therefore, we aimed to determine rates of ICD eligibility and use among patients seen in heart function clinics (HFCs) using chart-level data based on relevant ICD guidelines. We also aimed to determine reasons for nonimplantation, to identify significant predictors for device nonimplantation among eligible patients, and to determine outcomes among device nonrecipients at 3 years follow-up.

Methods {#sec1}
=======

Study population {#sec1.1}
----------------

As part of a quality-improvement initiative, the Arrhythmia Expert Working Group of the Alberta Health Services Cardiovascular and Stroke Strategic Clinical Network performed a retrospective review of all consecutive patients at 2 tertiary HFCs in Alberta, Canada, from 2013 to 2015. We chose this study period to allow adequate time for implementation of the 2012 American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society Focused Update and to take advantage of electronic medical records, which were widely used in HFCs. HFCs are defined as clinics where various cardiac pathologies are treated, including both preserved and reduced ejection fractions, and cater toward the optimization of heart failure therapy among all patients. Patient inclusion criteria included all of the following: age \> 18 years, history of heart failure, etiology of cardiomyopathy, and New York Heart Association (NYHA) functional class and left ventricular ejection fraction (LVEF) documented within 2 years of enrolment into the study. Patients were excluded if they had an ICD before the study period.

Patients active as of January 1 of each year (2013-2015) were screened, and baseline demographics, clinical indications, and comorbid disease were abstracted from the chart. Assessments of LVEF were taken closest to the most recent clinic visit. LVEF measurement modalities included magnetic resonance imaging, echocardiogram, and multigated acquisition scan. If more than 1 modality was used, the hierarchy of magnetic resonance imaging, multigated acquisition, echocardiography, myocardial perfusion imaging test, or other was followed. Chart reviewers were independent of the HFC physicians. At 3 years follow-up, device nonrecipients were identified as alive or deceased, and a cause of death was identified using hospital discharge summaries for those deceased in hospital.

ICD eligibility {#sec1.2}
---------------

Eligibility criteria were based on the Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on ICD use in Canada, the 2008 American College of Cardiology/American Heart Association/Heart Rhythm Society ICD and Cardiac Resynchronization Therapy (CRT) Guidelines, the 2012 American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society Focused Update, and the 2013 Canadian Cardiovascular Society Guidelines for CRT.[@bib6], [@bib7], [@bib8], [@bib9] Patients met guideline criteria for an ICD if they met the following criteria: (1) ischemic cardiomyopathy; (2) LVEF ≤ 0.35; (3) NYHA class I to III and an absence of revascularization within 3 months or acute myocardial infarction within 40 days and on adequate medical therapy for ≥ 3 months of determined device eligibility; or (1) nonischemic cardiomyopathy; (2) LVEF ≤ 0.35; (3) NYHA class II to III; CRT: (1) sinus rhythm, (2) LVEF ≤ 0.35, (3) NYHA class II to IV, (4) QRS duration ≥ 130 ms and left bundle branch block, or (5) QRS duration ≥ 150 ms and non--left bundle branch block ([Table 1](#tbl1){ref-type="table"}).Table 1ICD eligibility criteriaICDCRTCardiomyopathySinus rhythmIschemicNonischemicLVEF ≤ 0.35NYHA I-IIINYHA II-IIINYHA II-IVLVEF ≤ 0.35LVEF ≤ 0.35QRS ≥ 130 ms and LBBBQRS ≥ 150 ms and non-LBBB[^1]

Reasons for nonimplantation {#sec1.3}
---------------------------

Among device nonrecipients, reasons for nonimplantation were collected on a yearly basis and determined by reviewing physician letters who attended an HFC, electrophysiology consults, and nurses' notes. Reasons for nonimplantation included patient preference, medical reason (life expectancy \< 1 year, poor quality of life, severe chronic kidney disease \[glomerular filtration rate \< 30 mL/min\], or significant comorbidities) and technical reason (not medically optimized or LVEF improved on subsequent tests). When a patient was eligible during multiple years of the study period, only 1 reason was collected per year.

Outcomes {#sec1.4}
--------

The primary outcome for this study was to determine rates of ICD eligibility and use. Secondary outcomes were to identify reasons for nonimplantation, to determine predictors for device nonimplantation in eligible patients, and to determine outcomes among device nonrecipients at 3 years follow-up.

Statistical analysis {#sec1.5}
--------------------

Baseline demographics were presented as a count, mean (standard deviation), or median (interquartile range \[IQR\]). Characteristics were stratified into "never eligible" patients and patients who "met guideline criteria" and then were further stratified into device recipients and device nonrecipients. Device recipients and nonrecipients were compared using Kruskal--Wallis tests for continuous variables and chi-square tests for categorical variables. We used multivariable logistic regression to explore patient factors associated with device nonimplantation. We included candidate variables if the univariable association had a *P* value of ≤ 0.25. Stepwise variable selection was used to determine the final model, and variables were considered significant with a *P* value of \< 0.05.[@bib10] We used Stata version 14 (StataCorp LP, College Station, TX) to conduct our analysis.

This study was approved by the Health Research Ethics Board of the University of Alberta (Pro00063905) and the Conjoint Human Research Ethics Board Calgary, Alberta (REB 15-1176).

Results {#sec2}
=======

Baseline demographics {#sec2.1}
---------------------

Baseline demographics are shown in [Table 2](#tbl2){ref-type="table"}. The median age was 70 years (IQR, 59-80), the majority were male (67%), 35% of patients had ischemic cardiomyopathy, and the mean LVEF was 0.40 (IQR, 0.28-0.53). Compared with patients who received an ICD, device nonrecipients were more likely to be aged more than 75 years (39% vs 24%, *P* \< 0.001), to have a lower LVEF (median 26.1 vs 27.7, *P* = 0.036), and to be more likely to have a history of kidney disease (20.1% vs 13.1%, *P* = 0.037) and cancer (10% vs 5%, *P* = 0.013) ([Supplemental Table S1](#appsec1){ref-type="sec"}).Table 2Baseline demographicsCharacteristicAll patientsPatients meeting guideline criteriaNever device eligible*P* valuePatients, N1239553686Age (y), median (IQR)70 (59-80)69 (59-78)71 (59-81)0.454Age \> 75 y, n (%)456 (36)204 (36.8)252 (36.7)0.971Sex: male, n (%)858 (69.2)451 (81.5)407 (59.3)\< 0.001Heart failure cause, ischemic, n (%)587 (47.3)250 (45.2)337 (49.1)0.172\
\< 0.001LVEF, mean (SD)40.5 (0.28-0.53)26.9 (8.0)51.5 (8.5)NYHA class, n, (%) I352 (28.4)115 (20.8)237 (34.5)\< 0.001 II500 (40.4)242 (43.8)258 (37.6) III241 (19.5)129 (23.4)112 (16.4) IV11 (0.8)8 (1.4)3 (0.4) Not reported135 (10.9)59 (10.6)76 (11.1)Cardiovascular comorbidities, n (%)Atrial fibrillation508 (41.0)205 (37.0)303 (44.2)0.010 Paroxysmal139 (11.2)54 (9.7)85 (12.4)0.763 Persistent285 (23.0)119 (21.5)166 (24.2) Not reported84 (6.7)32 (5.7)52 (7.5)Atrial flutter39 (3.2)17 (3.1)22 (3.2)0.920Hypertension628 (50.6)268 (48.5)360 (52.5)0.162Hyperlipidemia113 (9.1)54 (9.7)59 (8.6)0.503Myocardial infarction272 (21.9)161 (29.1)111 (16.2)\< 0.001Cerebrovascular disease130 (10.4)59 (10.6)71 (10.3)0.864Diabetes393 (31.7)185 (33.4)208 (40.8)0.008 Complicated23 (1.8)8 (1.4)15 (2.2)0.214 Uncomplicated284 (22.9)141 (25.4)143 (20.8) Not reported86 (6.9)36 (6.5)50 (7.2)Peripheral vascular disease41 (3.3)19 (3.4)22 (3.2)0.198Other comorbidities, n (%)Kidney disease227 (18.3)106 (19.1)121 (17.6)0.497 Mild115 (9.2)51 (9.2)64 (9.3)0.765 Moderate-severe72 (5.8)35 (6.3)37 (5.3) Not reported40 (3.2)20 (3.6)20 (2.9)Liver disease3 (0.2)2 (0.2)1 (0.1)0.729Cancer128 (10.3)51 (9.2)77 (11.2)0.250 Active16 (1.2)4 (0.7)12 (1.7)0.387 Remission95 (7.6)39 (7.0)56 (8.1) Not reported17 (1.3)8 (1.4)9 (1.3)Dementia13 (1.1)8 (1.4)5 (0.7)0.221[^2]

Device eligibility and use {#sec2.2}
--------------------------

A total of 1935 patients in HFCs were identified over the study period ([Fig. 1](#fig1){ref-type="fig"}). Of these, 696 were excluded because of missing information, such as no NYHA class or LVEF documented within 2 years of study enrolment or a prior ICD implant, leaving 1239 patients for our analysis. Of the final cohort, 45% of patients (n = 553) met guideline criteria for an ICD, and of those, 36% (n = 198) received a device. Among device nonrecipients, 52% (n = 185) had no documented reason for nonimplantation. Yearly rates of device nonrecipients having no documented reason for nonimplant were 33% (2013), 32% (2014), and 19% (2015).Figure 1Patient flow diagram. LVEF, left ventricular ejection fraction; HF, heart failure; NYHA, New York Heart Association.

Yearly rates of patients meeting guideline criteria ranged from 32% to 37% ([Fig. 2](#fig2){ref-type="fig"}), and yearly rates of device use among those meeting guideline criteria ranged from 19% to 36% ([Fig. 2](#fig2){ref-type="fig"}).Figure 2Eligibility and use rates according to the year.

Reasons for nonimplantation {#sec2.3}
---------------------------

Documented reasons for nonimplantation among those meeting guideline criteria included patient preference (48%), technical reason (35%), and medical reason (17%) ([Fig. 3](#fig3){ref-type="fig"}). Patient factors significantly associated with nonimplantation among those meeting guideline criteria were age \> 75 years (odds ratio \[OR\], 1.91; 95% confidence interval \[CI\], 1.31-2.82; *P* = 0.001) and a history of cancer (OR, 2.26; 95% CI, 1.07-4.78; *P* = 0.033) ([Table 3](#tbl3){ref-type="table"}). After adjustment, age \> 75 years (OR, 1.48; 95% CI, 1.03-2.12; *P* = 0.033) was the only factor significantly associated with nonimplantation among nonrecipients who lacked a documented reason for nonimplant. Among nonrecipients aged \> 75 years, the most commonly documented reason for nonimplantation was patient preference (56%), followed by a medical reason (25%) and a technical reason (19%).Figure 3Reasons for nonimplant according to the year.Table 3Factors associated with nonimplantation in patients meeting guideline criteria and nonrecipients lacking a documented reason for nonimplant\
Associated factorMet guideline criteriaNonrecipients lacking a documented reason for nonimplantUnivariate analysisFinal modelUnivariate analysisFinal modelOR (95% CI)*P*OR (95% CI)*P*OR (95% CI)*P*OR (95% CI)*P*Age \> 75 y**1.93 (1.32-2.83)0.0011.92 (1.31-2.82)0.0011.48 (1.03-2.12)0.0331.48 (1.03-2.12)0.033**Male0.98 (0.66-1.46)0.9321.01 (0.67-1.52)0.965LVEF \< 30%1.12 (0.79-1.59)0.5070.90 (0.63-1.29)0.576Ischemic0.83 (0.59-1.17)0.2840.87 (0.60-1.24)0.432NYHA class I (ref)1.01.0 II1.06 (0.67-1.66)0.8140.97 (0.61-1.53)0.892 III0.72 (0.44-1.19)0.2000.75 (0.44-1.28)0.291 IV0.98 (0.23-4.10)0.9741.71 (0.54-5.42)0.359 Not reported1.69 (0.82-3.47)0.1521.32 (0.72-2.43)0.377Atrial fibrillation1.27 (0.88-1.83)0.2011.38 (0.96-1.96)0.078Hypertension0.83 (0.59-1.17)0.2850.94 (0.66-1.34)0.745Hyperlipidemia0.59 (0.33-1.04)0.0670.55 (0.31-0.98)0.0430.68 (0.35-1.35)0.274Myocardial Infarction0.81 (0.55-1.18)0.2730.91 (0.61-1.35)0.630Diabetes0.91 (0.63-1.31)0.6190.85 (0.57-1.26)0.418Peripheral vascular disease1.08 (0.40-2.88)0.8810.93 (0.32-2.72)0.897Cerebrovascular disease0.96 (0.55-1.70)0.9000.82 (0.42-1.61)0.566Kidney disease1.66 (1.03-2.68)0.0391.32 (0.85-2.05)0.222Cancer**2.47 (1.18-5.18)0.0172.26 (1.07-4.78)0.033**1.65 (0.98-2.80)0.061Dementia3.52 (0.43-28.79)0.2411.66 (0.44-6.24)0.456[^3][^4]

Outcomes {#sec2.4}
--------

At 3 years follow-up, all patients meeting guideline criteria had follow-up data available. A total of 27% (96/355) of device nonrecipients were deceased. Among the nonrecipients who lacked a documented reasons for nonimplant, 32% (60/185) were deceased. Some 45% of patients (43/96) died in hospital, and the remaining 55% (53/96) died out of hospital and a cause of death could not be identified. A cardiac cause of death was identified in 26% (25/96), 9% (8/96) died of cancer, 7% (7/96) died of renal failure, and 3% (3/96) died of complications from an infection. Among nonrecipients aged \> 75 years, 39% (n = 55) were deceased. A cardiac cause of death was identified in 25% (n = 14).

Discussion {#sec3}
==========

In this large, population-based study of ICD eligibility and use, we found that half of patients seen in the HFC met guideline criteria for a primary prevention device, and among those, one-third received an ICD. Patient preference was the most common reason for nonimplantation among nonrecipients; however, half of nonrecipients lacked a documented reason for nonimplantation. At 3 years follow-up, approximately one-quarter of nonrecipients were deceased.

Previous studies[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17] assessing ICD eligibility have shown that 45% to 51% of patients were eligible for a primary prevention device. Our study demonstrated similar eligibility rates (45%) for primary prevention ICD therapy, and this is most likely explained by the use of comparable guideline eligibility criteria[@bib17] and similar patient cohorts.[@bib10] The retrospective study by Lyons et al.[@bib10] was performed in an HFC included in our study and may be a factor contributing to similarities between the 2 studies. We showed that rates did not differ when including a larger population who was representative of patients in HFCs across the province.

Studies investigating ICD use have demonstrated variable results.[@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17] A single-center retrospective review found use rates among "truly eligible" patients (those who met guideline criteria and lacked a reasons for nonimplantation) ranged from 76% to 86%.[@bib10] Our study showed rates of ICD use that were lower at approximately 36%, even though the 2 studies had similar patient cohorts. A possible explanation for the difference in rates may be the study methodology. We excluded implants occurring before the study period, which provided a more accurate estimation of device use at that time, and we also used an LVEF cutoff of 0.35, which was reflective of the guideline recommendations used during our study period. Other studies[@bib11], [@bib13] have also demonstrated significant underuse of ICD therapy with rates as low as 13%.[@bib14] Regardless, there is a clear need to better understand potential system and physician barriers, and to develop strategies to improve the use of primary prevention ICD therapy for appropriate patients in HFCs.

Our study reports that half of device nonrecipients were missing a documented reason for nonimplantation. This is similar to another single-center, retrospective study of patients in HFCs, which found that 42% of the time, a documented reason for nonimplantation was missing among device nonrecipients.[@bib10] This highlights the need to implement quality improvement initiatives geared toward emphasizing complete and clearly documented medical records consisting of patient preferences, risks, and contraindications. Patient preference was also the most commonly documented reason for nonimplantation among patients meeting guideline criteria and accounted for 48% of reasons for nonadherence in our study. Prior work[@bib10], [@bib13], [@bib18] has also demonstrated high rates of patient preference as a reason for nonimplantation. It is important to address patient barriers for ICD use because they are a vital part of the implant process; however, patients also may be influenced by physician discussion around the device indication, procedure, and follow-up care. Retrospective reviews have provided some insight into patient reason for refusal, that is, older age and the presence of comorbidities[@bib10], [@bib14], [@bib15] were associated with device nonadherence. These were also found to be significant predictors associated with device nonadherence in our analysis. We also found similar predictors of nonimplantation with older age, a lower ejection fraction, and a history of kidney disease being significantly associated with nonimplantation. One possible explanation for a lower ejection fraction being associated with nonimplantation is that this group is perceived as too sick for device therapy; however, further investigation is needed. In long-term follow-up, we found approximately one-third of device nonrecipients were deceased. Among deaths in the hospital, more than one-quarter were identified as cardiac, and it is possible some of these patients may have benefited from ICD therapy.

Of note, the latest Canadian ICD guidelines have been published[@bib22] and are relatively consistent with the guidelines used in this study. The new guidelines focus on persistent reduced ejection fraction, optimal medical therapy, and time postrevascularization and myocardial infarction. A significant change is noted in the exclusion of NYHA as an eligibility criterion. Another important study is the **D**efibrill**a**tor Implantation in Patients With **N**on**i**schemic **S**ystolic **H**eart Failure (DANISH) trial.[@bib23] This large randomized clinical trial in patients with nonischemic systolic heart failure demonstrated that ICD therapy was not associated with a lower mortality when compared with medical therapy.

There are several initiatives known to improve adherence to device-based therapy.[@bib24], [@bib25], [@bib26], [@bib27], [@bib28] The IMPROVE HF registry is a quality-improvement registry designed to evaluate the outpatient management of systolic heart failure and to assess the effect of various improvement interventions, such as education initiatives, reminder systems, and quality reports. With use of the IMPROVE HF registry, ICD use increased dramatically from 50.1% to 77.5%.[@bib25] The Get With The Guidelines Heart Failure initiative is another effective prospective quality improvement registry that has shown improvement in the use of CRT implants among patients with heart failure.[@bib28] In addition, several patients are never referred to a specialist or appropriately followed up. The use of electronic screening tools has significantly improved appropriate ICD referrals.[@bib29] Initiatives such as these could be implemented at device implanting centers to improve use among patients meeting guideline criteria.

Study limitations {#sec3.1}
-----------------

There are limitations to our study that warrant discussion. First, this was a retrospective study in which abstraction errors and variability in medical chart completeness pose a risk. However, to minimize this, each site adhered to strict definitions of device eligibility. Second, approximately one-quarter of patients were excluded because of missing heart failure data, NYHA class, or LVEF, which could have affected our findings. Third, survival of device nonrecipients was not compared with the device recipients. Fourth, there was no documented reason for nonadherence in approximately one-half of device nonrecipients. Fifth, more than one-half of deaths were out of hospital, and determining cause of death was not possible. Even among hospitalized deaths, the cause of death was dependent on the detail provided in the discharge summary. Sixth, the study was performed in one province, and the results may not be generalizable to other countries with different healthcare systems. Seventh, reasons for nonimplantation was not collected. This information could be useful when counseling patients on the advantages and disadvantages of primary prevention device therapy.

Conclusion {#sec4}
==========

In this population-based study of complex device eligibility and use, we found that one-third of patients meeting guideline criteria for ICD therapy receive a device. Among those who did not receive a device, a documented reason for nonimplantation was missing in more than one-half of patients. To develop initiatives to improve use, a better understanding of patient, physician, and system barriers to device implantation is needed. Documenting reasons for ineligibility should be encouraged.
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[^1]: CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

[^2]: IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SD, standard deviation.

[^3]: Bold values indicate significant values.

[^4]: CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; OR, odds ratio.
